|
|
Radiotherapy for Pediatric Central Nervous
System Tumors: A Regional Cancer Centre Experience
Glenn Bauman, Barbara
Fisher, Elizabeth Cairney, Adriana Ranger, A. Rashid Dar, Jill
Ross, Larry Stitt, David Macdonald
Division
of Radiation Oncology, London Regional Cancer Centre (LRCC) and Department of
Oncology, University of Western Ontario (UWO), London, Ontario, Canada (G.B.,
B.F., A.R.D.). Department of Pediatrics, London Health Sciences Centre
(LHSC) and UWO, Canada (E.C.). Department of Pediatrics and Department of
Clinical Neurologic Sciences, LHSC and UWO, Canada (A.R.).
London Regional Cancer Centre, London, Ontario, Canada
(J.R.). Department of Epidemiology and Biostatistics, UWO, London, Ontario,
Canada (L.S.).
Division of Medical Oncology, LRCC, Departments of
Oncology and Department of Clinical Neurologic Sciences, UWO, Canada (D.M.).
Introduction. The
purpose of this review was to analyze outcomes for pediatric patients treated
for more common (non-low grade glioma) primary central nervous system (CNS)
tumors at a Regional (tertiary) Cancer Center.
Comparison to reported results from other regional centres and results from the
contemporary literature were made.
Material
and methods. The records of pediatric patients treated with
radiotherapy at the London Regional Cancer Center (LRCC) for more common
(non-low grade glioma) primary CNS tumors between 1980 and 2001 were
reviewed.
Details regarding tumor presentation, treatment and outcome were analyzed.
Results.
Eighty-eight patients were eligible for the review.
Twenty-nine patients with malignant glioma, 37 patients with medulloblastoma or
primitive neuroectodermal tumor (PNET), 15 patients with brainstem glioma, 4
with ependymoma and 3 with germ cell tumors were treated during this time
period.
Average follow-up for the group was 5 years (range 4 months to 19 years).
Five-year overall, progression free and cause specific survival were 45, 42 and
50%, respectively.
For patients with malignant glioma median progression free and overall survival
was 20 and 29 months.
For patients with brainstem glioma median progression free and overall survival
was 9 and 13 months.
For medulloblastoma, 5-year progression free, and overall survival was 60 and
59%.
Conclusions.
Results of this retrospective review of pediatric patients treated at a regional
cancer center for primary CNS tumors (other than low grade glioma) were
comparable to contemporary results reported by other Canadian centers and North
American co-operative group trials.
Keywords: brain tumor, pediatric, radiation
Copyright
©
2004 Kluwer Academic Publishers.
All rights reserved
Source: http://ipsapp009.kluweronline.com/IPS/content/ext/x/J/5042/I/119/A/12/abstract.htm
|
